VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 143 filers reported holding VANDA PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.91 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $100,000 | -40.1% | 10,100 | -34.3% | 0.00% | – |
| Q2 2022 | $167,000 | -37.7% | 15,372 | -35.2% | 0.00% | – |
| Q1 2022 | $268,000 | -15.7% | 23,704 | +16.8% | 0.00% | -100.0% |
| Q4 2021 | $318,000 | -73.6% | 20,300 | -71.1% | 0.00% | -75.0% |
| Q3 2021 | $1,203,000 | +158.7% | 70,139 | +224.5% | 0.00% | +100.0% |
| Q2 2021 | $465,000 | +72.9% | 21,617 | +31.9% | 0.00% | 0.0% |
| Q4 2019 | $269,000 | -57.4% | 16,388 | -32.2% | 0.00% | -60.0% |
| Q4 2018 | $632,000 | +229.2% | 24,180 | +187.9% | 0.01% | +400.0% |
| Q3 2018 | $192,000 | -86.8% | 8,400 | -91.2% | 0.00% | -85.7% |
| Q4 2017 | $1,453,000 | +24116.7% | 95,500 | +23775.0% | 0.01% | – |
| Q1 2017 | $6,000 | -98.8% | 400 | -98.8% | 0.00% | -100.0% |
| Q4 2016 | $510,000 | +7185.7% | 32,000 | +7900.0% | 0.00% | – |
| Q3 2016 | $7,000 | -81.6% | 400 | -91.1% | 0.00% | – |
| Q1 2016 | $38,000 | – | 4,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 1,532,000 | $27,423,000 | 3.23% |
| Stonepine Capital Management, LLC | 300,000 | $5,370,000 | 3.16% |
| Palo Alto Investors LP | 4,155,670 | $74,386,000 | 3.13% |
| GREAT POINT PARTNERS LLC | 497,531 | $8,906,000 | 1.73% |
| Avoro Capital Advisors LLC | 988,270 | $17,690,000 | 1.37% |
| UNIVERSITY OF NOTRE DAME DU LAC | 157,781 | $2,824,000 | 0.79% |
| Birchview Capital, LP | 68,000 | $1,217,000 | 0.63% |
| Cheyne Capital Management (UK) LLP | 74,000 | $1,323,000 | 0.48% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 352,604 | $6,311,000 | 0.43% |
| 361 CAPITAL LLC | 119,554 | $2,140,000 | 0.41% |